查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1269441

末稍血管扩张药市场- 全球产业分析，规模，占有率，成长，趋势，及预测，2023-2031年

Peripheral Vasodilator Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 130 Pages | 商品交期: 2-10个工作天内

价格

末稍血管扩张药市场- 调查范围:

TMR 的研究报告《全球末稍血管扩张药市场》为了提供2023年～2031年预测期间上关于市场指标的宝贵知识和见解，不仅探讨了过去的增长趋势，还调查了当前的增长趋势和机会。本报告以 2023 年为基准年，2031 年为预测年。提供2017年到2031年的全球末稍血管扩张药市场收益。并刊载2023年2031年的全球末稍血管扩张药市场年复合成长率。

本报告透过广泛研究作成。初步研究中由分析师对主要意见领袖、行业领袖和舆论製造者进行访谈，并进行大部分研究工作。二次研究则参考主要公司的产品资料、年报、新闻稿和相关文件，来掌握末稍血管扩张药市场。

该报告深入探讨全球末稍血管扩张药市场的竞争格局。锁定全球末稍血管扩张药市场活动的主要企业，并对每家公司进行了不同属性的分析。介绍企业概要，财务状况，最近的趋势，SWOT等全球末稍血管扩张药市场企业的属性。

目录

第1章 序文

  • 市场定义和范围
  • 市场区隔
  • 主要的调查目的
  • 调查亮点

第2章 前提条件与调查手法

第3章 摘要整理:全球市场

第4章 市场概要

  • 简介
    • 定义
    • 产业的演进与发展
  • 概要
  • 市场动态
    • 促进因素
    • 阻碍因素
    • 机会
  • 全球市场的分析与预测，2017-2031年
    • 市场收益预测

第5章 主要洞察

  • 全球疾病盛行率及发病率(各主要国家
  • 各地区/世界各国的法规Scenario
  • COVID-19疫情对产业的影响

第6章 全球市场分析·预测:各药物类型

  • 简介和定义
  • 主要的发现与发展
  • 市场价值预测:各药物类型，2017-2031年
    • 钙拮抗剂
    • 直接作用型血管扩张药
    • α-肾上腺素阻断剂
    • 钾流通管道活性化剂
    • 硝酸药
    • 其他
  • 市场魅力分析:各药物类型

第7章 全球市场分析·预测:各流通管道

  • 简介&定义
  • 主要调查结果·发展情形
  • 市场价值预测:各流通管道，2017-2031年
    • 医院药局
    • 零售药局
    • 线上药局
  • 市场魅力分析:各流通管道

第8章 全球市场分析·预测:各地区

  • 主要调查结果
  • 市场规模预测:各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美
    • 中东·非洲地区
  • 市场魅力分析:各地区

第9章 北美市场分析·预测

  • 简介
    • 主要调查结果
  • 市场价值预测:各药物类型，2017-2031年
    • 钙拮抗剂
    • 直接作用型血管扩张药
    • α-肾上腺素阻断剂
    • 钾流通管道活性化剂
    • 硝酸药
    • 其他
  • 市场价值预测:各流通管道，2017-2031年
    • 医院药局
    • 零售药局
    • 线上药局
  • 市场价值预测:各国，2017-2031年
    • 美国
    • 加拿大
  • 市场魅力分析
    • 各药物类型
    • 各流通管道
    • 各国

第10章 欧洲市场分析与预测

  • 简介
    • 主要调查结果
  • 市场价值预测:各药物类型，2017-2031年
    • 钙拮抗剂
    • 直接作用型血管扩张药
    • α-肾上腺素阻断剂
    • 钾流通管道活性化剂
    • 硝酸药
    • 其他
  • 市场价值预测:各流通管道，2017-2031年
    • 医院药局
    • 零售药局
    • 线上药局
  • 市场价值预测:国家·小各地区，2017-2031年
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 其他欧洲
  • 市场魅力分析
    • 各药物类型
    • 各流通管道
    • 各国/辅助region

第11章 亚太地区的市场分析与预测

  • 简介
    • 主要调查结果
  • 市场价值预测:各药物类型，2017-2031年
    • 钙拮抗剂
    • 直接作用型血管扩张药
    • α-肾上腺素阻断剂
    • 钾流通管道活性化剂
    • 硝酸药
    • 其他
  • 市场价值预测:各流通管道，2017-2031年
    • 医院药局
    • 零售药局
    • 线上药局
  • 市场价值预测:国家·小各地区，2017-2031年
    • 中国
    • 日本
    • 印度
    • 澳洲·纽西兰
    • 其他亚太地区
  • 市场魅力分析
    • 各药物类型
    • 各流通管道
    • 各国/辅助region

第12章 南美的市场分析·预测

  • 简介
    • 主要调查结果
  • 市场价值预测:各药物类型，2017年～2031年
    • 钙拮抗剂
    • 直接作用型血管扩张药
    • α-肾上腺素阻断剂
    • 钾流通管道活性化剂
    • 硝酸药
    • 其他
  • 市场价值预测:各流通管道，2017-2031年
    • 医院药局
    • 零售药局
    • 线上药局
  • 市场价值预测:国家·小各地区，2017-2031年
    • 巴西
    • 墨西哥
    • 其他南美国家地区
  • 市场魅力分析
    • 各药物类型
    • 各流通管道
    • 各国/辅助region

第13章 中东·非洲的市场分析与预测

  • 简介
    • 主要调查结果
  • 市场价值预测:各药物类型，2017-2031年
    • 钙拮抗剂
    • 直接作用型血管扩张药
    • α-肾上腺素阻断剂
    • 钾流通管道活性化剂
    • 硝酸药
    • 其他
  • 市场价值预测:各流通管道，2017-2031年
    • 医院药局
    • 零售药局
    • 线上药局
  • 市场金额预测:国家·小各地区，2017-2031年
    • GCC各国
    • 南非
    • 其他中东·非洲
  • 市场魅力分析
    • 各药物类型
    • 各销售管道
    • 各国/辅助region

第14章 竞争情形

  • 市场企业-竞争矩阵(企业各层级，不同企业规模)
  • 市场占有率分析:各企业，2022年
  • 企业简介
    • Pfizer, Inc.
    • Novartis AG
    • GSK plc
    • AstraZeneca
    • Merck & Co., Inc.
    • Sanofi
    • Bayer AG
    • Abbott Laboratories
    • Bristol-Myers Squibb Company
    • Boehringer Ingelheim International GmbH
    • Teva Pharmaceutical Industries Ltd.
    • Viatris, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Lupin
Product Code: TMRGL85487

Peripheral Vasodilator Drugs Market - Scope of Report:

TMR's report on the global peripheral vasodilator drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global peripheral vasodilator drugs market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global peripheral vasodilator drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the peripheral vasodilator drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global peripheral vasodilator drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global peripheral vasodilator drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global peripheral vasodilator drugs market.

The report delves into the competitive landscape of the global peripheral vasodilator drugs market. Key players operating in the global peripheral vasodilator drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global peripheral vasodilator drugs market profiled in this report.

Key Questions Answered in Global Peripheral Vasodilator Drugs Market Report:

  • What is the sales/revenue generated by peripheral vasodilator drugs across all regions during the forecast period?
  • What are the opportunities in the global peripheral vasodilator drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Peripheral Vasodilator Drugs Market - Research Objectives and Research Approach:

The comprehensive report on the global peripheral vasodilator drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global peripheral vasodilator drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global peripheral vasodilator drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Peripheral Vasodilator Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Peripheral Vasodilator Drugs Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Disease Prevalence & Incidence Rate globally with key countries
  • 5.2. Regulatory Scenario by Region/globally
  • 5.3. COVID-19 Pandemics Impact on Industry

6. Global Peripheral Vasodilator Drugs Market Analysis and Forecast, by Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Drug Type, 2017-2031
    • 6.3.1. Calcium Channel Blockers
    • 6.3.2. Direct-acting Vasodilators
    • 6.3.3. Alpha-adrenergic Blockers
    • 6.3.4. Potassium Channel Activators
    • 6.3.5. Nitrates
    • 6.3.6. Others
  • 6.4. Market Attractiveness Analysis, by Drug Type

7. Global Peripheral Vasodilator Drugs Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Online Pharmacies
  • 7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global Peripheral Vasodilator Drugs Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Region

9. North America Peripheral Vasodilator Drugs Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Drug Type, 2017-2031
    • 9.2.1. Calcium Channel Blockers
    • 9.2.2. Direct-acting Vasodilators
    • 9.2.3. Alpha-adrenergic Blockers
    • 9.2.4. Potassium Channel Activators
    • 9.2.5. Nitrates
    • 9.2.6. Others
  • 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Value Forecast, by Country, 2017-2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Drug Type
    • 9.5.2. By Distribution Channel
    • 9.5.3. By Country

10. Europe Peripheral Vasodilator Drugs Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Type, 2017-2031
    • 10.2.1. Calcium Channel Blockers
    • 10.2.2. Direct-acting Vasodilators
    • 10.2.3. Alpha-adrenergic Blockers
    • 10.2.4. Potassium Channel Activators
    • 10.2.5. Nitrates
    • 10.2.6. Others
  • 10.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
  • 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Spain
    • 10.4.5. Italy
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Drug Type
    • 10.5.2. By Distribution Channel
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Peripheral Vasodilator Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Type, 2017-2031
    • 11.2.1. Calcium Channel Blockers
    • 11.2.2. Direct-acting Vasodilators
    • 11.2.3. Alpha-adrenergic Blockers
    • 11.2.4. Potassium Channel Activators
    • 11.2.5. Nitrates
    • 11.2.6. Others
  • 11.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Retail Pharmacies
    • 11.3.3. Online Pharmacies
  • 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Drug Type
    • 11.5.2. By Distribution Channel
    • 11.5.3. By Country/Sub-region

12. Latin America Peripheral Vasodilator Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Type, 2017-2031
    • 12.2.1. Calcium Channel Blockers
    • 12.2.2. Direct-acting Vasodilators
    • 12.2.3. Alpha-adrenergic Blockers
    • 12.2.4. Potassium Channel Activators
    • 12.2.5. Nitrates
    • 12.2.6. Others
  • 12.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.3.1. Hospital Pharmacies
    • 12.3.2. Retail Pharmacies
    • 12.3.3. Online Pharmacies
  • 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Drug Type
    • 12.5.2. By Distribution Channel
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Peripheral Vasodilator Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Type, 2017-2031
    • 13.2.1. Calcium Channel Blockers
    • 13.2.2. Direct-acting Vasodilators
    • 13.2.3. Alpha-adrenergic Blockers
    • 13.2.4. Potassium Channel Activators
    • 13.2.5. Nitrates
    • 13.2.6. Others
  • 13.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.3.1. Hospital Pharmacies
    • 13.3.2. Retail Pharmacies
    • 13.3.3. Online Pharmacies
  • 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Drug Type
    • 13.5.2. By Distribution Channel
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (by tier and size of companies)
  • 14.2. Market Share Analysis, by Company, 2022
  • 14.3. Company Profiles
    • 14.3.1. Pfizer, Inc.
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. Financial Overview
      • 14.3.1.4. SWOT Analysis
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Novartis AG
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. Financial Overview
      • 14.3.2.4. SWOT Analysis
      • 14.3.2.5. Strategic Overview
    • 14.3.3. GSK plc
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. Financial Overview
      • 14.3.3.4. SWOT Analysis
      • 14.3.3.5. Strategic Overview
    • 14.3.4. AstraZeneca
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. Financial Overview
      • 14.3.4.4. SWOT Analysis
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Merck & Co., Inc.
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. Financial Overview
      • 14.3.5.4. SWOT Analysis
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Sanofi
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. Financial Overview
      • 14.3.6.4. SWOT Analysis
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Bayer AG
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. Financial Overview
      • 14.3.7.4. SWOT Analysis
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Abbott Laboratories
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. Financial Overview
      • 14.3.8.4. SWOT Analysis
      • 14.3.8.5. Strategic Overview
    • 14.3.9. Bristol-Myers Squibb Company
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. Financial Overview
      • 14.3.9.4. SWOT Analysis
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Boehringer Ingelheim International GmbH
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. Financial Overview
      • 14.3.10.4. SWOT Analysis
      • 14.3.10.5. Strategic Overview
    • 14.3.11. Teva Pharmaceutical Industries Ltd.
      • 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.11.2. Product Portfolio
      • 14.3.11.3. Financial Overview
      • 14.3.11.4. SWOT Analysis
      • 14.3.11.5. Strategic Overview
    • 14.3.12. Viatris, Inc.
      • 14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.12.2. Product Portfolio
      • 14.3.12.3. Financial Overview
      • 14.3.12.4. SWOT Analysis
      • 14.3.12.5. Strategic Overview
    • 14.3.13. Sun Pharmaceutical Industries Ltd.
      • 14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.13.2. Product Portfolio
      • 14.3.13.3. Financial Overview
      • 14.3.13.4. SWOT Analysis
      • 14.3.13.5. Strategic Overview
    • 14.3.14. Lupin
      • 14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.14.2. Product Portfolio
      • 14.3.14.3. Financial Overview
      • 14.3.14.4. SWOT Analysis
      • 14.3.14.5. Strategic Overview

List of Tables

  • Table 01: Global Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 02: Global Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 03: Global Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 04: North America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 05: North America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 06: North America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: Europe Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 08: Europe Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Asia Pacific Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 11: Asia Pacific Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 12: Asia Pacific Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 13: Latin America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 14: Latin America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 15: Latin America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 16: Middle East & Africa Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 17: Middle East & Africa Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 18: Middle East & Africa Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Peripheral Vasodilator Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 03: Global Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 04: Global Peripheral Vasodilator Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 05: Global Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 06: Global Peripheral Vasodilator Drugs Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 07: Global Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 08: North America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 09: North America Peripheral Vasodilator Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 10: North America Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 11: North America Peripheral Vasodilator Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 12: North America Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 13: North America Peripheral Vasodilator Drugs Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 14: North America Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 15: Europe Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 16: Europe Peripheral Vasodilator Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 17: Europe Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 18: Europe Peripheral Vasodilator Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 19: Europe Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 20: Europe Peripheral Vasodilator Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 21: Europe Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 22: Asia Pacific Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 23: Asia Pacific Peripheral Vasodilator Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 24: Asia Pacific Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 25: Asia Pacific Peripheral Vasodilator Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 26: Asia Pacific Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 27: Asia Pacific Peripheral Vasodilator Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 28: Asia Pacific Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Latin America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 30: Latin America Peripheral Vasodilator Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 31: Latin America Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 32: Latin America Peripheral Vasodilator Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 33: Latin America Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 34: Latin America Peripheral Vasodilator Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 35: Latin America Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 36: Middle East & Africa Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 37: Middle East & Africa Peripheral Vasodilator Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 38: Middle East & Africa Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 39: Middle East & Africa Peripheral Vasodilator Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 40: Middle East & Africa Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 41: Middle East & Africa Peripheral Vasodilator Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 42: Middle East & Africa Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 43: Global Peripheral Vasodilator Drugs Market Share Analysis, by Company, 2022